
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
<a href="https://news.google.com/rss/articles/CBMingJBVV95cUxQYjUwY3ZSaEtKVks5T2V5OUZpYnFHWjYtUF9kOWhCekVDYnA5dmgzUXB6cDNtUWJMekdzUWpkUmEtWmxnM0llRHRjV2FnWVBDS1JTVWZMV0xKMmNkSG1LMmdvMEg4UlhOOHJoNnpONGtBVlpLWUQ5X3NqaEFQM0VDTEI0dUxYWjF1N1ZyR2FqSTNBMS1ac0JmeDVMRVU0ZnB6UWhwdzVhS3hNNWpGZGJXQVEzUW12alU1R2ZBdkZRVDBrd1pRTjhyT3RzWDdtWmFIWjBtajVfN2U1WFozc0NfUk9pc1RCRFlJQ0hqNlRVejl6aWRVMkl1XzNFeVhZWWp4LURHT1IxMzRDU055bFJCdnN1UkdyY2RzZ3l1ZFR3?oc=5" target="_blank">INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
